GCP
KDNY

GSA Capital Partners’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

GSA Capital Partners’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,383
Closed -$235K – 1946
2021
Q4 		$235K Buy
+14,383
New +$205K 0.03% 1112
2020
Q4 		– Sell
-6,848
Closed -$83K – 1702
2020
Q3 		$83K Buy
6,848
+501
+8% +$6.71K 0.01% 1150
2020
Q2 		$73K Buy
+6,347
New +$87.5K 0.04% 518
2020
Q1 		– Sell
-11,769
Closed -$69K – 1684
2019
Q4 		$69K Buy
+11,769
New +$64K 0.01% 1359
2016
Q4 		– Sell
-3,800
Closed -$236K – 2018
2016
Q3 		$236K Buy
+3,800
New +$269K 0.01% 1512
2016
Q2 		– Sell
-3,960
Closed -$254K – 1965
2016
Q1 		$254K Buy
3,960
+760
+24% +$61.5K 0.02% 1387
2015
Q4 		$450K Buy
3,200
+740
+30% +$101K 0.02% 1225
2015
Q3 		$238K Buy
+2,460
New +$293K 0.01% 1494

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

GSA Capital Partners's KDNY Position: Q1 2022 in Review

GSA Capital Partners sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2022, closing a stake of 14,383 shares — an estimated $235K sold.

GSA Capital Partners first reported a position in KDNY in Q3 2015 and held it in 8 quarters. The position peaked at $450K in Q4 2015. 105 funds tracked by Wall St. Rank hold KDNY as of Q1 2022.

  • GSA Capital Partners reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • GSA Capital Partners sold 14,383 Chinook Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $235K.
  • GSA Capital Partners first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2015 and held it in 8 quarters.
  • GSA Capital Partners's Chinook Therapeutics, Inc. Common Stock position peaked at $450K in Q4 2015.
  • 105 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.